> Details

Hamdouchi, Chafiq; Keyser, Heather; Collins, Elizabeth; Jaramillo, Carlos; De Diego, Jose Eugenio; Spencer, Charles D.; Dempsey, Jack Alan; Anderson, Bryan D.; Leggett, Tillie; Stamm, Nancy B.; Schultz, Richard M.; Watkins, Scott A.; Cocke, Kim; Lemke, Stephanie; Burke, Teresa F.; Beckmann, Richard P.; Dixon, Jeffrey T.; Gurganus, Thomas M.; Rankl, Nancy B.; Houck, Keith A.; Zhang, Faming; Vieth, Michal; Espinosa, Juan; Timm, David E.; [...]

The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines
  • Contributor: Hamdouchi, Chafiq; Keyser, Heather; Collins, Elizabeth; Jaramillo, Carlos; De Diego, Jose Eugenio; Spencer, Charles D.; Dempsey, Jack Alan; Anderson, Bryan D.; Leggett, Tillie; Stamm, Nancy B.; Schultz, Richard M.; Watkins, Scott A.; Cocke, Kim; Lemke, Stephanie; Burke, Teresa F.; Beckmann, Richard P.; Dixon, Jeffrey T.; Gurganus, Thomas M.; Rankl, Nancy B.; Houck, Keith A.; Zhang, Faming; Vieth, Michal; Espinosa, Juan; Timm, David E.; [...]
  • Published: American Association for Cancer Research (AACR), 2004
  • Published in: Molecular Cancer Therapeutics, 3 (2004) 1, Seite 1-9
  • Language: English
  • DOI: 10.1158/1535-7163.1.3.1
  • ISSN: 1535-7163; 1538-8514
  • Origination:
  • Footnote:
  • Description: Abstract The protein kinase family represents an enormous opportunity for drug development. However, the current limitation in structural diversity of kinase inhibitors has complicated efforts to identify effective treatments of diseases that involve protein kinase signaling pathways. We have identified a new structural class of protein serine/threonine kinase inhibitors comprising an aminoimidazo[1,2-a]pyridine nucleus. In this report, we describe the first successful use of this class of aza-heterocycles to generate potent inhibitors of cyclin-dependent kinases that compete with ATP for binding to a catalytic subunit of the protein. Co-crystal structures of CDK2 in complex with lead compounds reveal a unique mode of binding. Using this knowledge, a structure-based design approach directed this chemical scaffold toward generating potent and selective CDK2 inhibitors, which selectively inhibited the CDK2-dependent phosphorylation of Rb and induced caspase-3-dependent apoptosis in HCT 116 tumor cells. The discovery of this new class of ATP-site-directed protein kinase inhibitors, aminoimidazo[1,2-a]pyridines, provides the basis for a new medicinal chemistry tool to be used in the search for effective treatments of cancer and other diseases that involve protein kinase signaling pathways.
  • Access State: Open Access